Kezar Q3 net loss $23.1M; appoints new CEO, restructures to extend cash runway into 2026

Kezar Life Sciences, Inc.

2023-Q3 EPS reported -$0.96 revenue$7,000,000

Net loss of $23.1M ($0.32/share) vs $17.8M loss in Q3 2022; revenue of $7.0M from Everest upfront.
Cash, equivalents, marketable securities $218.2M at Sep 30, down from $276.6M at Dec 31, 2022.
Co-founder Christopher Kirk appointed CEO Nov 7, replacing John Fowler who remains on board.
Strategic restructuring pauses drug discovery, extends cash runway into late 2026; focuses on zetomipzomib and KZR-261.
Collaboration with Everest Medicines for zetomipzomib in Greater China, South Korea, SE Asia; Everest joins PALIZADE trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Kezar Life Sciences, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Kezar Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended September 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Kezar Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062918

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.